A 5-Year- study on Children with Acute Myelocytic Leukemia/AML, Ahvaz Shafa Hospital (1996-2001)

Reza Akramipour; M Pedram; KM Zandian; A Hashemi

Journal of Kermanshah University of Medical Sciences

Peer-reviewed Medical Quarterly

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Boards and Committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Reviewer and AE Registration Form Support Contact Us

Authors Guide Submit Manuscript

A 5-Year- study on Children with Acute Myelocytic Leukemia/AML, Ahvaz Shafa Hospital (1996-2001)

Author(s):

Reza Akramipour^1,*,

M Pedram¹,

KM Zandian¹,

A Hashemi¹

1Iran

Journal of Kermanshah University of Medical Sciences:Vol. 11, issue 2; e80674

Published online:Sep 19, 2007

Article type:Research Article

Received:Nov 27, 2004

Accepted:May 01, 2007

How to Cite:Akramipour R, Pedram M, Zandian K, Hashemi A. A 5-Year- study on Children with Acute Myelocytic Leukemia/AML, Ahvaz Shafa Hospital (1996-2001). J Kermanshah Univ Med Sci. 2007;11(2):e80674. doi:

Abstract

Introduction: AML is the second most common leukemia in children after ALL. The rate of AML in 14-year-old children is reported to be 6.6 cases per million. This study reviews 40 children with AML within 5 years. These patients have been evaluated for clinical findings and overall survival.

Materials & Methods: All Patients with AML have been evaluated from 1996 to 2000 for clinical findings, age, gender, lab data, AML subtypes, geographic distribution, treatment results and overall survival. Myeloblast, over 30 percent, was compatible with AML. FAB classification was applied for AML subtypes. BM flocytometry and special staining were applied, if necessary. CBC test was performed through sysmex counter.

Results: In this study, 40 cases were diagnosed to have AML during 5 years, 60% of patients were male & 40% female, among whom 17.5% were less than one year old. Age distribution was between 2 to 15 years old, and the most common clinical findings were bleeding, weakness, respiratory symptoms and pallor. More than 90 percent of patients suffered from anemia and thrombocytopenia. M3 was the most common subtype.

Conclusion: In this survey, overall survival was less than 35 percent, which proves that chemotherapy without BMT is an incomplete therapy; there was also no significant difference between sexes, but 17.5% of patients were less than one year old and 22.5% of them reported by parents to have anemia.

Keywords

leukemia

AML

Survival Rate

Fulltext

The full text of this article is available on PDF

Import into EndNote Import into BibTex

Share on

Comments

Number of Comments:0

Cited by

Scopus by DOI: 0
Last Update: 1 week ago
Scopus by Title: 0
Last Update: 1 week ago
Scopus by Title (Ref): 7
Last Update: 1 week ago
CrossRef: 0
Last Update: 4 hours ago

Metrics

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC

Search Relations

Author(s):

Reza Akramipour:[PubMed][Scholar]
M Pedram:[PubMed][Scholar]
KM Zandian:[PubMed][Scholar]
A Hashemi:[PubMed][Scholar]

Peer-reviewed Medical Quarterly

Outlines

A 5-Year- study on Children with Acute Myelocytic Leukemia/AML, Ahvaz Shafa Hospital (1996-2001)

Abstract

Fulltext

Last Update: 1 week ago

Last Update: 1 week ago

Last Update: 1 week ago

Last Update: 4 hours ago